Shutaishen: Subsidiary's STSP-0601 Injection Gets U.S. FDA Clinical Trial Approval

English summary

Shutaishen announced that its subsidiary Beijietai received an official letter from the U.S. FDA allowing clinical trials of STSP-0601 for bleeding in hemophilia A or B patients with inhibitors. The drug had previously obtained a drug registration certificate from China's NMPA in June 2026.